There are errors in the formatting of [Figure 3](#pone-0109437-g001){ref-type="fig"} and [Table 4](#pone-0109437-t001){ref-type="table"}.

![Common estimates where justified and indirect comparisons of all BID or QD dosing regimens of NOACs.\
Results are expressed from the respective main dose results of the phase 3 trials \[1\]--\[5\] in the intent-to-treat analysis for efficacy (Stroke and systemic embolism, ischemic stroke) and in the safety analysis for intracranial hemorrhage. AP, apixaban; BID, twice-daily dosing; CE, common estimate; CI, confidence interval; DE, dabigatran etexilate; EDOX, edoxaban; HR, hazard ratio; QD, once-daily dosing; RIVA, rivaroxaban; SE, systemic embolism; W, warfarin; aIn the ROCKET-AF trial, only ischemic strokes, excluding unspecified strokes, are reported. Note: bold and italic font marks significantly superior results.](pone.0109437.g001){#pone-0109437-g001}
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###### Analysis of results heterogeneity of NOACs vs warfarin.

![](pone.0109437.t001){#pone-0109437-t001-1}

                                                  Analysis of heterogeneity (meta-analysis FEM)                  
  ------------------------------ ------------------------------------------------------------------------------- --------------------------------------------------------------
  Stroke and systemic embolism        All dose groups: χ^2^  =  19.78, *df*  =  5, p = 0.001, I^2^  =  75%       
                                                                     **BID**                                                                 **QD**
                                                χ^2^  =  1.78, *df*  =  1, p = 0.18, I^2^  =  44%                 **χ^2^  =  0.01,** ***df*** ** =  1, p = 0.92, I^2^  =  0%**
  Ischemic/unspecified stroke         All dose groups: χ^2^  =  20.43, *df*  =  5, p = 0.001, I^2^  =  76%       
                                                                     **BID**                                                                 **QD**
                                          **χ^2^  =  1.31,** ***df*** ** =  1, p = 0.25, I^2^  =  24%**           **χ^2^  =  0.01,** ***df*** ** =  1, p = 0.94, I^2^  =  0%**
  All-cause mortality             **All dose groups: χ^2^  =  0.97,** ***df*** ** =  5, p = 0.96, I^2^  =  0%**  
                                                                     **BID**                                                                 **QD**
                                          **χ^2^  =  0.02,** ***df*** ** =  1, p = 0.90, I^2^  =  0%**            **χ^2^  =  0.00,** ***df*** ** =  1, p = 1.00, I^2^  =  0%**
  Intracranial hemorrhage             All dose groups: χ^2^  =  17.41, *df*  =  5, p = 0.004, I^2^  =  71%       
                                                                     **BID**                                                                 **QD**
                                          **χ^2^  =  0.92,** ***df*** ** =  1, p = 0.34, I^2^  =  0%**                 χ^2^  =  2.28, *df*  =  1, p = 0.13, I^2^  =  56%
  Major bleeding event               All dose groups: χ^2^  =  71.23, *df*  =  5, p = 0.00001, I^2^  =  93%      
                                                                     **BID**                                                                 **QD**
                                               χ^2^  =  10.02, *df*  =  1, p = 0.002, I^2^  =  90%                     χ^2^  =  7.32, *df*  =  1, p = 0.007, I^2^  =  86%

Given are the main results (including all dosages or the dose with most pronounced efficacy result)^\*^ and grouping by regimen (BID or QD) are displayed. BID, twice-daily dosing; FEM, fixed-effects meta-analysis; NOACs, novel oral anticoagulants; QD, once-daily dosing.

Note. Bold font marks nearly absence of heterogeneity, i.e., generation of a common estimate is justified.

\*Dose with most pronounced efficacy result: dabigatran 150 mg BID, apixaban 5/2.5 mg BID, rivaroxaban 20/15 mg QD, and edoxaban 60/30 mg QD.

Please see the corrected [Figure 3](#pone-0109437-g001){ref-type="fig"} here.

Please see the corrected [Table 4](#pone-0109437-t001){ref-type="table"} here.
